Lumretuzumab

Lumretuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Roche.

History

Lumretuzumab was part of a collaboration between Roche and Genmab, a Danish biotechnology company. The drug was designed to target and bind to the HER3 (human epidermal growth factor receptor 3) protein, which is often overexpressed in certain types of cancer.

Clinical trials

In 2015, Roche initiated a phase I clinical trial for lumretuzumab. The trial was designed to evaluate the safety, tolerability, and efficacy of the drug in patients with advanced solid tumors. However, the results of the trial were not as promising as hoped, and Roche decided to discontinue the development of lumretuzumab in 2017.

Mechanism of action

Lumretuzumab works by binding to the HER3 protein on the surface of cancer cells. This binding inhibits the ability of the HER3 protein to send signals that promote cell growth and survival, thereby slowing or stopping the growth of the cancer.

See also

• Monoclonal antibodies
• Cancer treatment
• Clinical trial
• Roche
• Genmab

Lumretuzumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski